Transactions with APP Pharmaceuticals, Inc. for Abraxis

Send us Feedback

Abraxis BioScience (ABII)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	STOCK CHART

	SEC FILINGS

ABII » Topics » Transactions with APP Pharmaceuticals, Inc.

This excerpt taken from the ABII 10-K filed Mar 12, 2010.

Transactions with APP Pharmaceuticals, Inc.

In connection with the separation on November 13, 2007, we entered into a number of agreements that governs the relationship between APP and us for a period of time after the separation. The agreements were entered into while we were still a wholly owned subsidiary of Old Abraxis. These agreements include: (i) a tax allocation agreement, (ii) a dual officer agreement, (iii) an employee matters agreement, (iv) a transition services agreement, (v) a manufacturing agreement, and (vi) various real estate leases. Transactions relating to these agreements recorded in our consolidated and combined statement of operations are summarized in the following table:


	Year Ended December 31,
	2009		2008		2007
	(in thousands)
Other revenue:
Net rental income	$	2,710	$	2,588	$	216
Cost of sales:
Manufacturing and distribution		1,398		1,676		33
Facility management fees		2,750		3,000		250
Selling, general and administrative expenses:
Net general and administrative costs		1,204		549		(111	)

These excerpts taken from the ABII 10-K filed Mar 6, 2009.

Transactions with APP Pharmaceuticals, Inc.


	Year Ended December 31,
	2008		2007
	(in thousands)
Other revenue:
Net rental income	$	2,588	$	216
Cost of sales:
Manufacturing and distribution		1,676		33
Facility management fees		3,000		250
Selling, general and administrative expenses:
Net general and administrative		549		(111	)

Transactions with APP Pharmaceuticals, Inc.

STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%">In connection with the separation on November 13, 2007, we entered into a number of agreements that governs the relationship between APP and us for a
period of time after the separation. The agreements were entered into while we were still a wholly owned subsidiary of Old Abraxis. These agreements include: (i) a tax allocation agreement, (ii) a dual officer agreement, (iii) an
employee matters agreement, (iv) a transition services agreement, (v) a manufacturing agreement, and (vi) various real estate leases. Transactions relating to these agreements recorded in our consolidated and combined statement of
operations are summarized in the following table:


	Year Ended December 31,
	2008		2007
	(in thousands)
Other revenue:
Net rental income	$	2,588	$	216
Cost of sales:
Manufacturing and distribution		1,676		33
Facility management fees		3,000		250
Selling, general and administrative expenses:
Net general and administrative		549		(111	)

This excerpt taken from the ABII 10-Q filed Nov 14, 2008.

Transactions with APP Pharmaceuticals, Inc.

In connection with the separation on November 13, 2007, we entered into a number of agreements that govern the relationship between APP and us for a period of time after the separation. The agreements were entered into while we were still a wholly owned subsidiary of Old Abraxis. These agreements include (i) a tax allocation agreement, (ii) an employee matters agreement, (iii) a transition services agreement, (iv) a manufacturing agreement and (v) various real estate leases. Transactions relating to these agreements recorded in our condensed consolidated and combined statement of operations are summarized in the following table:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2008		2007		2008		2007
	(in thousands)
Other revenue:
Net rental income	$	647	$	—	$	1,941	$	—
Cost of sales:
Manufacturing and distribution costs		331		—		1,172		—
Facility management fees		750		—		2,250		—
Selling, general and administrative
Net general and administrative costs		785		—		221		—

This excerpt taken from the ABII 10-Q filed Aug 14, 2008.

Transactions with APP Pharmaceuticals, Inc.

matters agreement, (iii) a transition services agreement, (iv) a manufacturing agreement and (v) various real estate leases. Transactions relating to these agreements recorded in our condensed consolidated and combined statement of operations are summarized in the following table:


	Three Months Ended June 30,					Six Months Ended June 30,
	2008			2007		2008			2007
	(in thousands)
Other revenue:
Net rental income	$	647		$	—	$	1,294		$	—
Cost of sales:
Manufacturing and distribution costs		534			—		841			—
Facility management fees		750			—		1,500			—
Selling, general and administrative
Net general and administrative costs		(189	)		—		(564	)		—

This excerpt taken from the ABII 10-Q filed May 15, 2008.

Transactions with APP Pharmaceuticals, Inc.

In connection with the separation on November 13, 2007, we entered into a number of agreements that govern the relationship between APP and us for a period of time after the separation. The agreements were entered into while we were still a wholly owned subsidiary of Old Abraxis. These agreements include (i) a tax allocation agreement, (ii) a dual officer agreement, (iii) an employee matters agreement, (iv) a transition services agreement, (v) a manufacturing agreement, and (vi) various real estate leases. Transactions relating to these agreements recorded in our condensed consolidated and combined statement of operations are summarized in the following table:


	Three Months Ended March 31,
	2008			2007
	(in thousands)
Other revenue:
Net rental income	$	647		$	—
Cost of sales:
Manufacturing and distribution costs		307			—
Facility management fees		750			—
Selling, general and administrative
Net general and administrative costs		(375	)		—

EXCERPTS ON THIS PAGE:

10-K	Mar 12, 2010

10-K (2 sections)	Mar 6, 2009

10-Q	Nov 14, 2008

10-Q	Aug 14, 2008

10-Q	May 15, 2008

Abraxis BioScience (ABII)

ABII » Topics » Transactions with APP Pharmaceuticals, Inc.

Table of Contents

EXCERPTS ON THIS PAGE:

RELATED TOPICS for ABII: